GammaDelta Therapeutics Ltd, a London, UK-based immunotherapy company, received seed funding from Abingworth, the international investment group dedicated to life sciences.
The amount of the deal was not disclosed.
The company, which also received support from three organizations, Cancer Research Technology (CRT), King’s College London and the Francis Crick Institute, will use the funds to advance its programs into the clinic.
Founded on pioneering research by Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute, funded in part by Cancer Research UK, into gamma delta (γδ) T cells, GammaDelta Therapeutics is focused on developing immunotherapies for cancer and potentially other diseases based on gamma delta (γδ) cells.
Peter Goodfellow, an advisor to Abingworth and formerly Senior Vice President for Discovery Research at GlaxoSmithKline, is Chairman of the board, which also includes, Prof. Hayday; Raj Mehta (Founder and Interim CEO) of CRT; Stephen Parker, Institutes Director; Mike Owen, formerly Senior Vice President for Biopharmaceuticals Research at GlaxoSmithKline; and Tim Haines, Managing Partner of Abingworth.
The company is being incubated at Abingworth’s London office.